{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:55:43Z","timestamp":1781650543798,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Discipline Construction Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary high-grade lacrimal gland (LG) mucoepidermoid carcinoma (MEC) is a rare condition that presents diagnostic and treatment challenges. In this study, we aimed to elucidate the diagnosis, treatment, and mutational landscape of high-grade LG MEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed clinical symptoms, radiological images, treatment, prognosis, histopathology, and mutational landscape of 20 patients with high-grade LG MEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Primary clinical presentation of high-grade LG MEC was proptosis (85%) with a low incidence of ocular pain (20%). CT scans showed frequent bone destruction (89.5%) and calcification (73.7%). MRI revealed hypointense areas on T2-weighted imaging (WI) in 85% of lesions and non-enhanced areas on contrast-enhanced T1WI in 95% of cases. All 20 patients with primary high-grade LG MEC underwent surgery and were stratified into 5 treatment groups. Multi-group analysis showed only the complete resection plus adjuvant radiotherapy group had significantly better RFS than the complete resection alone group (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0016), with no significant OS differences across groups. The rates of recurrence, metastasis, and mortality for patients in T4 stage were 77.8%, 71.4%, and 100%, respectively, while those in stages T1-3 were 25%, 75%, and 62.5%. Log-rank tests demonstrated superior long-term RFS and OS in T1\u20133 patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), whereas Gehan-Breslow-Wilcoxon tests yielded non-significant results. Whole-exome sequencing of tumors and adjacent normal tissues from 3 patients showed TP53 as the only consistent driver gene with missense mutations in all samples. Additionally, EGFR, DOCK2, GAN11, AKAP9, and SMC4 were identified as driver genes in 2 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High-grade LG MEC predominantly manifested as painless exophthalmos and the characteristic imaging included calcification, bone destruction, hypointense areas on T2WI, and non-enhanced areas on contrast-enhanced T1WI. Adjuvant radiotherapy after complete resection reduced recurrence and improved RFS but did not significantly elevate the overall survival rate of primary high-grade LG MEC patients. Prognosis is especially poor for T4 stage. Potential somatic variants identified within this small exploratory cohort, including TP53, EGFR, DOCK2, GAN11, AKAP9, and SMC4 may represent the potential therapeutic targets. Nevertheless, their clinical and prognostic relevance requires rigorous validation in larger independent patient cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-04784-y","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:15:58Z","timestamp":1776435358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary high-grade mucoepidermoid carcinoma of the lacrimal gland: retrospective clinical-pathologic analysis of 20 cases"],"prefix":"10.1186","volume":"26","author":[{"given":"Xushuang","family":"Zhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuetao","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"4784_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2022.03.008","volume":"239","author":"H Sun","year":"2022","unstructured":"Sun H, Cai R, Zhai C, Song W, Sun J, Bi Y. Primary Mucoepidermoid carcinoma of the lacrimal apparatus. Am J Ophthalmol. 2022;239:170\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"4784_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3341\/kjo.2018.0026","volume":"32","author":"SJ Hwang","year":"2018","unstructured":"Hwang SJ, Kim KH. High-grade mucoepidermoid carcinoma of the lacrimal gland. Korean J Ophthalmol. 2018;32(5):426\u20137.","journal-title":"Korean J Ophthalmol"},{"key":"4784_CR3","doi-asserted-by":"publisher","first-page":"1131587","DOI":"10.3389\/fonc.2023.1131587","volume":"13","author":"Y Wu","year":"2023","unstructured":"Wu Y, He W. crimal gland mucoepidermoid carcinoma with contralateral eye and systemic metastasis: A rare case report and review of the literature. Front Oncol. 2023;13:1131587.","journal-title":"Front Oncol"},{"issue":"1","key":"4784_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/jwas.jwas_35_21","volume":"10","author":"RJ Alfin","year":"2020","unstructured":"Alfin RJ, Alada JJ, Okwudire-Ejeh I, Mosugu O, Ramyil AV. J West Afr Coll Surg. 2020;10(1):26\u20139.","journal-title":"J West Afr Coll Surg"},{"issue":"3","key":"4784_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00002341-199309000-00002","volume":"9","author":"JA Eviatar","year":"1993","unstructured":"Eviatar JA, Hornblass A. Mucoepidermoid carcinoma of the lacrimal gland: 25 cases and a review and update of the literature. Ophthalmic Plast Reconstr Surg. 1993;9(3):170\u201381.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"4784_CR6","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.ophtha.2013.03.030","volume":"120","author":"L Sarah","year":"2013","unstructured":"Sarah L, vH, Andr\u00e9 F, Marta P, Marianne HT, Jan UP, Steffen H, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology. 2013;120:2130\u20138.","journal-title":"Ophthalmology"},{"key":"4784_CR7","first-page":"316","volume":"22","author":"Q Wei","year":"2011","unstructured":"Wei Q, Robert C, Xuequan H, Mingming L, Zheng Qin Y. Adenoid cystic carcinoma of the lacrimal gland: CT and MRI findings. Eur J Ophthalmol. 2011;22:316\u20139.","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"4784_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371\u2013. \u2013\u200985.e18.","journal-title":"Cell"},{"issue":"7471","key":"4784_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333\u20139.","journal-title":"Nature"},{"issue":"1","key":"4784_CR10","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1038\/srep02650","volume":"3","author":"D Tamborero","year":"2013","unstructured":"Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3(1):2650.","journal-title":"Sci Rep"},{"issue":"6127","key":"4784_CR11","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358.","journal-title":"Science"},{"issue":"3","key":"4784_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1755-3768.2012.02402.x","volume":"91","author":"SL von Holstein","year":"2013","unstructured":"von Holstein SL, Coupland SE, Briscoe D, Le Tourneau C, Heegaard S. Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological survey. Acta Ophthalmol. 2013;91(3):195\u2013206.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"4784_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/bjophthalmol-2017-311538","volume":"103","author":"Y Stephanie Ming","year":"2019","unstructured":"Stephanie Ming Y, Yoon-Duck K, Hyun Jin S, Yukihiro I, Stephanie SL, Kyung In W. Lacrimal gland pleomorphic adenoma and malignant epithelial tumours: clinical and imaging differences. Br J Ophthalmol. 2019;103(2):264.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"4784_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/ICU.0000000000000515","volume":"29","author":"A G\u00fcnd\u00fcz","year":"2018","unstructured":"G\u00fcnd\u00fcz A, Ye\u015filta\u015f Y, Shields C. Overview of benign and malignant lacrimal gland tumors. Curr Opin Ophthalmol. 2018;29(5):458\u201368.","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"4784_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.survophthal.2020.04.001","volume":"65","author":"I Ramberg","year":"2020","unstructured":"Ramberg I, Toft P, Heegaard S. Carcinomas of the lacrimal drainage system. Surv Ophthalmol. 2020;65(6):691\u2013707.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"4784_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.18240\/ijo.2024.01.22","volume":"17","author":"H Yan","year":"2024","unstructured":"Yan H, Liu R, Wang N, Xu L, Guo Q, Li J, et al. Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis. Int J Ophthalmol. 2024;17(1):164\u201372.","journal-title":"Int J Ophthalmol"},{"key":"4784_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43856-022-00082-y","volume":"2","author":"G St\u00e5lhammar","year":"2022","unstructured":"St\u00e5lhammar G, Herrspiegel C. Long-term relative survival in uveal melanoma: a systematic review and meta-analysis. Commun Med (Lond). 2022;2:18.","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"4784_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/1078-0432.CCR-16-0720","volume":"23","author":"H Kang","year":"2017","unstructured":"Kang H, Tan M, Bishop J, Jones S, Sausen M, Ha P, et al. Whole-exome sequencing of salivary gland mucoepidermoid carcinoma. Clin Cancer Res. 2017;23(1):283\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4784_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41698-024-00735-2","volume":"8","author":"X Wang","year":"2024","unstructured":"Wang X, Bai J, Yan J, Li B. The clinical outcome, pathologic spectrum, and genomic landscape for 454 cases of salivary mucoepidermoid carcinoma. NPJ Precis Oncol. 2024;8(1):238.","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"4784_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/his.12183","volume":"63","author":"T Nakano","year":"2013","unstructured":"Nakano T, Yamamoto H, Hashimoto K, Tamiya S, Shiratsuchi H, Nakashima T, et al. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status. Histopathology. 2013;63(3):378\u201392.","journal-title":"Histopathology"},{"issue":"1","key":"4784_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/1752-1947-2-320","volume":"2","author":"S Grisanti","year":"2008","unstructured":"Grisanti S, Amoroso V, Buglione M, Rosati A, Gatta R, Pizzocaro C, et al. Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: A case report and review of literature. J Med Case Rep. 2008;2(1):320.","journal-title":"J Med Case Rep"},{"key":"4784_CR22","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.oraloncology.2020.104824","volume":"107","author":"Y Wu","year":"2020","unstructured":"Wu Y, Han L, Sheng Y, Wu S. Cetuximab monotherapy for relapsing high-grade mucoepidermoid carcinoma: A case report and review of the literature. Oral Oncol. 2020;107:104824.","journal-title":"Oral Oncol"},{"issue":"6","key":"4784_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00066-012-0096-1","volume":"188","author":"D Milanovic","year":"2012","unstructured":"Milanovic D, Jeremic B, Kayser G, Rischke HC, Pfeiffer J, Henke A. Relapsing high grade mucoepidermoid carcinoma. Strahlenther Onkol. 2012;188(6):518\u201322.","journal-title":"Strahlenther Onkol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04784-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04784-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04784-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:18:05Z","timestamp":1781648285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04784-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4784"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04784-y","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the Helsinki Declaration and received approval from the ethics committee of the 3rd Medical Center of the Chinese PLA General Hospital (KS2023-014). Informed consent to participate was obtained from all of the participants or their authorized representatives in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}